Cite
MLA Citation
X Wu et al.. “357 GLS-010 (Zimberelimab), a novel fully human anti-PD-1 mAb in chinese patients with recurrent/metastatic cervical cancer: results from a multicenter, open-label, single-arm phase II trial.” International journal of gynecological cancer, vol. 30, n.d., p. A147. http://access.bl.uk/ark:/81055/vdc_100144712509.0x00001e